AI Terminal
PureTech Health plc
Director's Dealing • Jul 22, 2022
4932_dirs_2022-07-22_8c9fac91-dd9b-4ef5-a3f2-89ffc8e2b84e.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 3711T
PureTech Health PLC
22 July 2022
22 July 2022
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 21 July 2021 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 15 June 2022 immediately prior to the Company's Annual General Meeting of Stockholders. Each PDMR received vested ordinary shares on 22 July 2022.
The Company's total issued ordinary share capital is 288,689,450 shares after the share issuance to the PDMRs, 3,563,665 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Raju Kucherlapati
John LaMattina
Robert Langer
Kiran Mazumdar-Shaw
Marjorie Scardino
Christopher Viehbacher
2
Reason for the notification
a)
Position/status
Non-Executive Directors
b)
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
PureTech Health plc
b)
LEI
213800LVPDNO2Z9T9I39
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
| Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74 |
b)
Nature of the transaction
Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan.
c)
Price(s) and volume(s)
| Recipient | Price | Amount |
| Raju Kucherlapati | 0.01 GBP | 11,190 ordinary shares |
| John LaMattina | 0.01 GBP | 11,190 ordinary shares |
| Robert Langer | 0.01 GBP | 11,190 ordinary shares |
| Kiran Mazumdar-Shaw | 0.01 GBP | 11,190 ordinary shares |
| Marjorie Scardino | 0.01 GBP | 11,190 ordinary shares |
| Christopher Viehbacher | 0.01 GBP | 11,190 ordinary shares |
d)
Aggregated information
| - | Aggregated volume |
| - | Price |
| Price | Aggregate Volume |
| 0.01 GBP | 67,140 ordinary shares |
e)
Date of the transaction
22 July 2022
f)
Place of the transaction
London Stock Exchange (XLON)
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHPPUMPMUPPGBG